StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Reblozyl (luspatercept by Quarter

Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Reblozyl (luspatercept: $98M in Q2 2026, up 11.4% from a year earlier.

Latest, Q2 2026
98
Period ended Jun 30, 2026
Change on a year earlier
+11.4%
88 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue – Reblozyl (3) | 122 | 107 | 15 | 98 | 88 | 11 | 25 | 19 | 31”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202698+11.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026128+26.7%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 2025133+51.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025111+35.4%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202588+17.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025101+74.1%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202488+46.7%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202482+90.7%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202475+108.3%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202458+93.3%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202360+66.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202343+34.4%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202336+28.6%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202330+11.1%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202236–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202232–Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up reblozyl (luspatercept

Cite this data

StockData. (2026). Merck Reblozyl (luspatercept ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-reblozyl-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.